Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To evaluate the efficacy and safety of RT002 (DaxibotulinumtoxinA for injection) in the treatment of moderate to severe glabellar lines: a multicenter, randomized, double-blind, placebo-controlled phase III clinical study

Next Previous
Trial Profile

To evaluate the efficacy and safety of RT002 (DaxibotulinumtoxinA for injection) in the treatment of moderate to severe glabellar lines: a multicenter, randomized, double-blind, placebo-controlled phase III clinical study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daxibotulinumtoxin A (Primary)
  • Indications Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Fosun Pharmaceutical

Most Recent Events

  • 01 Dec 2024 Primary endpoint has been met. (Proportion of 2-point composite responders at week 4 post-treatment.), according to a results published in the Journal of Plastic, Reconstructive.
  • 01 Dec 2024 Status changed from recruiting to completed, according to a results published in the Journal of Plastic, Reconstructive.
  • 01 Dec 2024 Results published in the Journal of Plastic, Reconstructive and Aesthetic Surgery: JPRAS

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top